BioSyent (CVE:RX) Sets New 1-Year High – What’s Next?

BioSyent Inc. (CVE:RX)’s stock price hit a new 52-week high during trading on Friday . The company traded as high as C$11.98 and last traded at C$11.95, with a volume of 1111 shares. The stock had previously closed at C$11.61.

BioSyent Stock Performance

The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The stock has a market cap of C$138.50 million, a PE ratio of 19.35 and a beta of 0.93. The company’s 50-day moving average price is C$11.19 and its two-hundred day moving average price is C$10.51.

Insider Buying and Selling at BioSyent

In related news, Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total value of C$55,628.75. Also, Director Seyed Ahmad Ashrafi sold 2,320 shares of the company’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of C$10.95, for a total transaction of C$25,404.00. Insiders have sold 239,132 shares of company stock worth $2,661,482 over the last 90 days. Corporate insiders own 33.65% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.